Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Involuntary treatment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    158 result(s) found for: Involuntary treatment. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2012-000957-30 Sponsor Protocol Number: 191622-117 Start Date*: 2012-08-28
    Sponsor Name:Allergan Ltd.
    Full Title: BOTOX® for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in Patients with Multiple Sclerosis
    Medical condition: Urinary incontinence due to neurogenic detrusor overactivity (NDO) resulting from multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000507-44 Sponsor Protocol Number: D-FR-52120-223 Start Date*: 2016-06-29
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...
    Medical condition: Urinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003471-30 Sponsor Protocol Number: D-FR-52120-222 Start Date*: 2016-09-26
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...
    Medical condition: Urinary incontinence (UI) caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed) PT (Completed) CZ (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020944-37 Sponsor Protocol Number: 09/0127 Start Date*: 2011-10-31
    Sponsor Name:University College London
    Full Title: Pilot study to establish laboratory methods for urine Nerve Growth Factor (NGF) and immunohistochemical staining of the vanilloid receptor (TRPV1) in bladder biopsies, following open label treatmen...
    Medical condition: Neurogenic & Idiopathic detrusor overactivity in the bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10005046 Bladder incontinence LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000476-13 Sponsor Protocol Number: SP738 Start Date*: 2004-08-10
    Sponsor Name:Schwarz Biosciences GmbH
    Full Title: LONG-TERM OPEN-LABEL EXTENSION TRIAL FOR SUBJECTS COMPLETING THE PHASE 3 TRIAL OF FESOTERODINE (SP583) FOR THE TREATMENT OF OVERACTIVE BLADDER SYNDROME
    Medical condition: overactive bladder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000968-16 Sponsor Protocol Number: F1J-FR-HAAB Start Date*: 2008-11-18
    Sponsor Name:CeRePP
    Full Title: EFFICACY OF DULOXETINE IN THE TREATMENT OF URINARY INCONTINENCEAFTER PROSTATECTOMIE DUE TO CANCER
    Medical condition: We want to evaluate the effect of Duloxetine 40mg BID (80mg daily dose) on the number of urinary incontinence episodes as shown on a 74 days bladder diary, compared to placebo for male which had a...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046543 Urinary incontinence LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004192-41 Sponsor Protocol Number: A0221109 Start Date*: 2020-09-03
    Sponsor Name:Pfizer
    Full Title: LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR ...
    Medical condition: Urinary Bladder, Neurogenic
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000784-33 Sponsor Protocol Number: TacTremorConversion Start Date*: 2017-07-31
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Effect of Envarsus conversion on tacrolimus-associated tremor in renal transplant patients. An open-label, single centre, prospective pharmacodynamic/pharmacokinetic clinical study
    Medical condition: Tacrolimus-associated tremor
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10044565 Tremor PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004898-30 Sponsor Protocol Number: 191622-121 Start Date*: 2013-07-18
    Sponsor Name:Allergan Ltd
    Full Title: Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age
    Medical condition: Urinary Incontinence due to Neurogenic Detrusor Overactivity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) AT (Completed) IT (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-006299-39 Sponsor Protocol Number: 191622-082-01 Start Date*: 2008-04-23
    Sponsor Name:Allergan
    Full Title: A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respira...
    Medical condition: Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046543 Urinary incontinence LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004036-36 Sponsor Protocol Number: 178-MA-1008 Start Date*: 2016-07-18
    Sponsor Name:Astellas Pharma Global development, Inc
    Full Title: A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi- Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While ...
    Medical condition: Over active bladder (OAB) in men with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000464-17 Sponsor Protocol Number: 191622-137 Start Date*: 2014-06-17
    Sponsor Name:Allergan Limited
    Full Title: BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age
    Medical condition: Urinary Incontinence Due to Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) NO (Completed) PL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004877-26 Sponsor Protocol Number: 191622-120 Start Date*: 2013-07-18
    Sponsor Name:Allergan Ltd.
    Full Title: BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age
    Medical condition: Urinary Incontinence Due to Neurogenic Detrusor Overactivity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) AT (Completed) IT (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003135-19 Sponsor Protocol Number: SD-809-C-23 Start Date*: 2015-02-06
    Sponsor Name:Auspex Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA
    Medical condition: Tardive Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed) CZ (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001890-15 Sponsor Protocol Number: SD-809-C-18 Start Date*: 2014-11-12
    Sponsor Name:Auspex Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA
    Medical condition: Tardive Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005772-13 Sponsor Protocol Number: AMISU_L_01008 Start Date*: 2008-01-28
    Sponsor Name:sanofi-aventis Zrt.
    Full Title: Comparative efficacy of amisulpride vs. risperidone on cognitive functions in patients with chronic schizophrenia.
    Medical condition: measure of overall cognitive functioning in chronic schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001891-73 Sponsor Protocol Number: SD-809-C-20 Start Date*: 2014-11-12
    Sponsor Name:Auspex Pharmaceuticals, Inc.
    Full Title: AN OPEN-LABEL, LONG-TERM SAFETY STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA
    Medical condition: Tardive Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-002900-16 Sponsor Protocol Number: CAFQ056A2203 Start Date*: 2007-10-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-...
    Medical condition: The main objective of this study is to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001685-35 Sponsor Protocol Number: ADT-2022-003 Start Date*: 2022-12-27
    Sponsor Name:Adeptio Pharmaceuticals Limited
    Full Title: Randomized, double-blind, placebo controlled clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia.
    Medical condition: Tardive dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001214-16 Sponsor Protocol Number: BXL628 02 16 Start Date*: 2007-07-03
    Sponsor Name:BIOXELL SPA
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, multi-centre, Phase IIb, study to determine the effect of BXL628 in women with detrusor overactivity
    Medical condition: Overactive Bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020853 Hypertonic bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) NL (Completed) GB (Completed) EE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 15:31:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA